SCHEMBL20537339

SCHEMBL20537339

Cc1ccc2[nH]c3c(c2c1)CCC[C@H]3NC(C)c1ccccc1

nearest known ligand 0.78

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.78
KCNH2 Q12809 1/20 0.78
GAA P10253 1/20 0.58
CASP6 P55212 1/20 0.58
PRMT5 O14744 2/20 0.54
SIRT1 Q96EB6 3/20 0.54
RECQL P46063 1/20 0.50
SIRT2 Q8IXJ6 1/20 0.50
CDC42 P60953 1/20 0.48
RB1 P06400 5/20 0.46
BRD3 Q15059 2/20 0.45
MEN1 O00255 1/20 0.44
GLA P06280 1/20 0.44
MAPT P10636 1/20 0.44
ALOX15 P16050 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CDKN1A P38936 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4149725 1.00 CYP2D6 (0.78) CYP2D6KCNH2GAACASP6PRMT5
SCHEMBL4194153 1.00 CYP2D6 (0.78) CYP2D6KCNH2GAACASP6PRMT5
SCHEMBL4199294 1.00 CYP2D6 (0.78) CYP2D6KCNH2GAACASP6PRMT5
SCHEMBL5461901 1.00 CYP2D6 (0.78) CYP2D6KCNH2GAACASP6PRMT5
SCHEMBL4195673 1.00 CYP2D6 (0.78) CYP2D6KCNH2GAACASP6PRMT5
SCHEMBL4194377 1.00 CYP2D6 (0.78) CYP2D6KCNH2GAACASP6PRMT5
SCHEMBL4172408 1.00 CYP2D6 (0.78) CYP2D6KCNH2GAACASP6PRMT5
SCHEMBL20537338 1.00 CYP2D6 (0.78) CYP2D6KCNH2GAACASP6PRMT5
Hydrochloric Acid SCHEMBL4152184 0.99 CYP2D6 (0.77) CYP2D6KCNH2GAACASP6PRMT5
Hydrochloric Acid SCHEMBL4165920 0.99 CYP2D6 (0.77) CYP2D6KCNH2GAACASP6PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110914270-B Preparation method of pirlindole enantiomer and salt thereof 社会医疗技术员技术股份公司 2022-05-03 CN claimed
CN-110831943-B Method for producing piperazine rings for the synthesis of pyrazinocarbazole derivatives 社会医疗技术员技术股份公司 2022-05-03 CN claimed
EP-3612534-B1 PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) 2021-12-22 EP claimed
US-20200190098-A1 PROCESS FOR THE PREPARATION OF PIRLINDOLE ENANTIOMERS AND ITS SALTS TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) 2020-06-18 US claimed
US-20200131186-A1 PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) 2020-04-30 US claimed
CN-110914270-A Preparation method of pirlindole enantiomer and salt thereof 社会医疗技术员技术股份公司 2020-03-24 CN claimed
CN-110831943-A Method for producing piperazine rings for the synthesis of pyrazinocarbazole derivatives 社会医疗技术员技术股份公司 2020-02-21 CN claimed
EP-3392251-A1 PROCESS FOR THE PREPARATION OF PIRLINDOLE ENANTIOMERS AND ITS SALTS TECNIMEDE-SOCIEDADE TECNICO-MEDICINAL, S.A. (PT) 2018-10-24 EP claimed
EP-3392250-A1 PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES TECNIMEDE-SOCIEDADE TECNICO-MEDICINAL, S.A. (PT) 2018-10-24 EP claimed
CN-110914270-B Preparation method of pirlindole enantiomer and salt thereof 社会医疗技术员技术股份公司 2022-05-03 CN disclosed
CN-110831943-B Method for producing piperazine rings for the synthesis of pyrazinocarbazole derivatives 社会医疗技术员技术股份公司 2022-05-03 CN disclosed
EP-3612534-B1 PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) 2021-12-22 EP disclosed
US-11008327-B2 Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) 2021-05-18 US disclosed
US-11008328-B2 Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) 2021-05-18 US disclosed
US-20200190098-A1 PROCESS FOR THE PREPARATION OF PIRLINDOLE ENANTIOMERS AND ITS SALTS TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) 2020-06-18 US disclosed
US-20200131186-A1 PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) 2020-04-30 US disclosed
CN-110914270-A Preparation method of pirlindole enantiomer and salt thereof 社会医疗技术员技术股份公司 2020-03-24 CN disclosed
CN-110831943-A Method for producing piperazine rings for the synthesis of pyrazinocarbazole derivatives 社会医疗技术员技术股份公司 2020-02-21 CN disclosed
EP-3392251-A1 PROCESS FOR THE PREPARATION OF PIRLINDOLE ENANTIOMERS AND ITS SALTS TECNIMEDE-SOCIEDADE TECNICO-MEDICINAL, S.A. (PT) 2018-10-24 EP disclosed
EP-3392250-A1 PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES TECNIMEDE-SOCIEDADE TECNICO-MEDICINAL, S.A. (PT) 2018-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200190098-A1 PROCESS FOR THE PREPARATION OF PIRLINDOLE ENANTIOMERS AND ITS SALTS PIR, DRD1, DRD4 CYP2D6 29/4885KCNH2 1544/4885GAA 3662/4885
US-11008327-B2 Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole PIR, DRD5, DRD1 CYP2D6 102/4885KCNH2 1118/4885GAA 3836/4885
US-20200131186-A1 PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES PIR, CYP3A5, DRD5 CYP2D6 188/4885KCNH2 523/4885GAA 4284/4885
US-11008328-B2 Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole PIR, DRD1, DRD5 CYP2D6 156/4885KCNH2 1899/4885GAA 3573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.